Abstract 573P
Background
Recent studies have observed a substantial reduction in quality of life (QoL) in the first 6-months following cytoreductive surgery (CRS), which takes at least a year to return to baseline. The Modified Glasgow Prognostic Score (mGPS) is a reliable predictor of oncologic outcomes in several malignancies. We investigated its utility in predicting the six-month QoL in post-CRS patients.
Methods
Patients undergoing cytoreductive surgery were prospectively enrolled in this study. Based on the preoperative serum levels of CRP and albumin, the patients were stratified into mGPS of 0, 1, and 2. The European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) was administered at 6th month following the surgery. The association between prognostic scores and QoL was measured using one-way ANOVA test.
Results
A total of 66 patients were enrolled between July 2021 and March 2023. Sixty-one patients (92.4 %) completed the questionnaires. The mean age of the study population was 50.94±10.7 years. The ovarian carcinoma was the most common primary site (n=54; 88.5%), followed by pseudomyxoma peritonei (n=4; 6.5 %), and appendicular neoplasm (n=3; 5%). The mGPS scores of 0, 1, and 2 were noted in 28 (45.9%), 26 (42.6%), and 7 (11.5 %) patients, respectively. With the increase in mGPS, a statistically significant decline was noted in global health status (p=0.0032), physical functioning (p=0.017), role functioning (p=0.001), fatigue (p=0.0071), pain (p=0.0037), insomnia (p<0.001), and constipation (p<0.001). However, emotional functioning, cognitive functioning, social functioning, nausea-vomiting, dyspnoea, appetite loss, constipation, diarrhoea and financial difficulties were similar across the prognostic score groups.
Conclusions
High mGPS can portend an inferior short-term quality of life in post-CRS patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.